

Bioassay Interpretation

Intake assessment methods

Intake Retention Fractions

Dose assessment

Learning Objectives

- Define the intake retention fraction and identify compilations of values for it
- Describe the methods for estimating intakes from bioassay data
- Interpret intake values in terms of regulatory limits

Methods for Quantitative Assessment of Intakes

- **Whole Body or Lung Counting:**
 - Feasible for x- or gamma-ray emitters
 - Also for energetic beta particles - can be detected by their *bremsstrahlung*
- **Excreta analysis:**
 - 24-hour urine collections - most widely used
 - 24-hour fecal collections
 - Material excised from wounds

Flow Chart

- **Analytical results**
 - **in vivo or in vitro**
- **Calculation of intake via intake retention fraction**
- **Calculation of CODE from dose coefficients**
- **Calculation of CEDE from effective dose coefficient**
- **Recording and reporting**

Intake Estimation

- **Must know date/time of intake; if not, assume it was halfway since last clean sample/count**
- **Use NUREG/CR-4884 to determine intake based on bioassay results**
- **Multiply intake by dose coefficient or**
- **Compare intake to ALI to get dose**
- **In U.S. must check if ALI is based on deterministic or stochastic limit**

NUREG/CR-4884

Interpretation of Bioassay Measurements

- **Tables of distribution and excretion (as fraction of initial intake) for both inhalation and ingestion of radionuclides, based on ICRP 30 models**
- **Values are referred to as Intake Retention Fractions (IRF'S), ICRP uses symbol $m(t)$**
- **Brief summary of models**
- **Element Data Sheets**
- **Examples**

Interpretation of Bioassay Measurements

Manuscript Completed: June 1987
Date Published: July 1987

Prepared by
Edward T. Lessard, Brookhaven National Laboratory, Upton, New York
Xia Yihua, Institute of Atomic Energy, Beijing, People's Republic of China
Kenneth W. Skrable, University of Lowell, Lowell, Massachusetts
George E. Chabot, University of Lowell, Lowell, Massachusetts
Clayton S. French, University of Lowell, Lowell, Massachusetts
Thomas R. Labone, University of Lowell, Lowell, Massachusetts
John R. Johnson, Chalk River Nuclear Laboratory, Ontario, Canada
Darrell R. Fisher, Battelle Pacific Northwest Laboratory, Richland, Washington
Richard Belanger, Science Applications International Corporation, San Diego, California
Joyce Landmann Lipsztein, Commissao Nacional de Energia Nuclear, Sao Paulo, Brazil

NRC Project Managers - B.G. Brooks and A. Brodsky

Prepared for
Division of Regulatory Applications
Office of Nuclear Regulatory Research
U.S. Nuclear Regulatory Commission
Washington, DC 20555
NRC FIN A-3289

CLASS W AMAD = 1 MICRON HALFLIFE= 1.92E+03 DAYS COBALT 60

TIME AFTER SINGLE INTAKE DAYS	FRACTION OF INITIAL INTAKE IN:				
	SYSTEMIC ORGANS	LUNGS	NASAL PASSAGES	GI TRACT	TOTAL BODY
1.00E-01	6.72E-02	2.76E-01	2.35E-01	5.68E-02	6.35E-01
2.00E-01	6.42E-02	2.65E-01	1.97E-01	1.04E-01	6.30E-01
3.00E-01	6.21E-02	2.56E-01	1.66E-01	1.42E-01	6.26E-01
4.00E-01	6.04E-02	2.47E-01	1.39E-01	1.73E-01	6.20E-01
5.00E-01	5.89E-02	2.40E-01	1.17E-01	1.99E-01	6.14E-01
6.00E-01	5.76E-02	2.33E-01	9.86E-02	2.18E-01	6.07E-01
7.00E-01	5.63E-02	2.26E-01	8.29E-02	2.33E-01	5.99E-01
8.00E-01	5.51E-02	2.21E-01	6.97E-02	2.43E-01	5.89E-01
9.00E-01	5.39E-02	2.16E-01	5.86E-02	2.50E-01	5.78E-01
1.00E+00	5.28E-02	2.11E-01	4.93E-02	2.53E-01	5.66E-01
2.00E+00	4.44E-02	1.77E-01	8.71E-03	1.93E-01	4.23E-01
3.00E+00	4.00E-02	1.60E-01	1.54E-03	1.07E-01	3.08E-01
4.00E+00	3.73E-02	1.50E-01	2.72E-04	5.40E-02	2.42E-01
5.00E+00	3.52E-02	1.44E-01	4.81E-05	2.68E-02	2.06E-01
6.00E+00	3.35E-02	1.41E-01	8.50E-06	1.38E-02	1.88E-01
7.00E+00	3.20E-02	1.38E-01	1.50E-06	7.68E-03	1.77E-01
8.00E+00	3.07E-02	1.35E-01	2.65E-07	4.76E-03	1.71E-01
9.00E+00	2.95E-02	1.33E-01	4.69E-08	3.35E-03	1.66E-01
1.00E+01	2.84E-02	1.32E-01	0.00E+00	2.66E-03	1.63E-01
2.00E+01	2.24E-02	1.15E-01	0.00E+00	1.77E-03	1.40E-01
3.00E+01	2.03E-02	1.01E-01	0.00E+00	1.53E-03	1.23E-01
4.00E+01	1.94E-02	8.88E-02	0.00E+00	1.33E-03	1.09E-01
5.00E+01	1.88E-02	7.78E-02	0.00E+00	1.15E-03	9.78E-02
6.00E+01	1.84E-02	6.83E-02	0.00E+00	1.00E-03	8.77E-02
7.00E+01	1.80E-02	5.98E-02	0.00E+00	8.68E-04	7.87E-02
8.00E+01	1.76E-02	5.25E-02	0.00E+00	7.53E-04	7.08E-02
9.00E+01	1.72E-02	4.60E-02	0.00E+00	6.53E-04	6.39E-02
1.00E+02	1.69E-02	4.03E-02	0.00E+00	5.67E-04	5.77E-02
2.00E+02	1.35E-02	1.07E-02	0.00E+00	1.37E-04	2.44E-02
3.00E+02	1.12E-02	2.83E-03	0.00E+00	3.29E-05	1.40E-02
4.00E+02	9.54E-03	7.41E-04	0.00E+00	7.95E-06	1.03E-02
5.00E+02	8.29E-03	1.93E-04	0.00E+00	1.92E-06	8.49E-03
6.00E+02	7.28E-03	4.99E-05	0.00E+00	4.62E-07	7.33E-03
7.00E+02	6.42E-03	1.28E-05	0.00E+00	1.11E-07	6.44E-03
8.00E+02	5.68E-03	3.29E-06	0.00E+00	2.69E-08	5.68E-03
9.00E+02	5.02E-03	8.42E-07	0.00E+00	0.00E+00	5.02E-03
1.00E+03	4.44E-03	2.15E-07	0.00E+00	0.00E+00	4.44E-03
2.00E+03	1.30E-03	0.00E+00	0.00E+00	0.00E+00	1.30E-03
4.00E+03	1.12E-04	0.00E+00	0.00E+00	0.00E+00	1.12E-04
5.00E+03	3.28E-05	0.00E+00	0.00E+00	0.00E+00	3.28E-05
7.00E+03	2.83E-06	0.00E+00	0.00E+00	0.00E+00	2.83E-06
8.00E+03	8.29E-07	0.00E+00	0.00E+00	0.00E+00	8.29E-07
9.00E+03	2.43E-07	0.00E+00	0.00E+00	0.00E+00	2.43E-07
1.00E+04	7.13E-08	0.00E+00	0.00E+00	0.00E+00	7.13E-08

CLASS W AMAD = 1 MICRON HALFLIFE= 1.92E+03 DAYS COBALT 60

TIME AFTER SINGLE INTAKE DAYS	FRACTION OF INITIAL INTAKE IN:			
	24-HOUR URINE	ACCUMULATED URINE	24-HOUR FECES	ACCUMULATED FECES
1.00E-01		3.35E-03		8.47E-04
2.00E-01		7.09E-03		1.83E-03
3.00E-01		1.01E-03		3.06E-03
4.00E-01		1.29E-02		4.82E-03
5.00E-01		1.57E-02		7.33E-03
6.00E-01		1.81E-02		1.07E-02
7.00E-01		2.02E-02		1.51E-02
8.00E-01		2.23E-02		2.05E-02
9.00E-01		2.42E-02		2.67E-02
1.00E+00	2.59E-02	2.59E-02	3.36E-02	3.36E-02
2.00E+00	1.10E-02	3.69E-02	8.87E-02	1.22E-01
3.00E+00	5.13E-03	4.21E-02	7.33E-02	1.95E-01
4.00E+00	3.05E-03	4.50E-02	4.26E-02	2.38E-01
5.00E+00	2.26E-03	4.73E-02	2.20E-02	2.60E-01
6.00E+00	1.90E-03	4.91E-02	1.12E-02	2.71E-01
7.00E+00	1.67E-03	5.09E-02	5.93E-03	2.77E-01
8.00E+00	1.51E-03	5.23E-02	3.42E-03	2.81E-01
9.00E+00	1.38E-03	5.37E-02	2.21E-03	2.83E-01
1.00E+01	1.27E-03	5.50E-02	1.62E-03	2.84E-01
2.00E+01	6.62E-04	6.35E-02	8.47E-04	2.93E-01
3.00E+01	4.48E-04	6.86E-02	7.07E-04	2.99E-01
4.00E+01	3.59E-04	7.22E-02	6.03E-04	3.05E-01
5.00E+01	3.11E-04	7.53E-02	5.23E-04	3.09E-01
6.00E+01	2.78E-04	7.79E-02	4.55E-04	3.13E-01
7.00E+01	2.50E-04	8.02E-02	3.97E-04	3.16E-01
8.00E+01	2.26E-04	8.24E-02	3.47E-04	3.19E-01
9.00E+01	2.05E-04	8.42E-02	3.03E-04	3.21E-01
1.00E+02	1.85E-04	8.58E-02	2.65E-04	3.23E-01
2.00E+02	6.86E-05	9.43E-02	7.00E-05	3.25E-01
3.00E+02	2.70E-05	9.52E-02	1.95E-05	3.17E-01
4.00E+02	1.27E-05	9.37E-02	6.24E-06	3.07E-01
5.00E+02	7.65E-06	9.13E-02	2.65E-06	2.97E-01
6.00E+02	5.63E-06	8.87E-02	1.59E-06	2.87E-01
7.00E+02	4.63E-06	8.61E-02	1.20E-06	2.77E-01
8.00E+02	3.99E-06	8.34E-02	1.01E-06	2.67E-01
9.00E+02	3.50E-06	8.09E-02	8.73E-07	2.57E-01
1.00E+03	3.09E-06	7.83E-02	7.73E-07	2.49E-01
2.00E+03	9.03E-07	5.61E-02	2.25E-07	1.74E-01
3.00E+03	2.65E-07	3.95E-02	6.62E-08	1.21E-01
4.00E+03	7.76E-08	2.77E-02	1.94E-08	8.47E-02
5.00E+03	2.27E-08	2.24E-02	0.00E+00	5.90E-02

Use of IRF's

- **Point estimates: each bioassay result divided by the appropriate IRF value gives a single estimate of intake; multiple values may be averaged**
- **Multiple values may give a single estimate of intake via unweighted least squares**
- **Multiple values may give a single estimate of intake via weighted least squares**

Bioassay Example

A worker spends some time in an area where Co-60 oxides are present. At the end of the quarter (70 days later), activity is detected in his routine urine sample. Follow-up samples reveal the following excretion pattern:

<u>Days after</u> <u>suspected exposure</u>	<u>24-hour urine</u> <u>activity (Bq)</u>
70	60
100	50
130	45

A lung count on day 70 revealed 0.25 MBq of Co-60. What is your best estimate of this individual's intake and dose?

Determine $m(t)$ values

We first look up the values supplied in NUREG/CR-4884 (Lessard et. al.) for class Y Co-60 (oxide). The IRF values are:

<u>Days after intake</u>	<u>Fraction of initial intake in:</u>	
	<u>24-hour urine</u>	<u>Lung</u>
70	2.97×10^{-5}	0.136
100	2.60×10^{-5}	0.130
200	1.99×10^{-5}	0.113
130 (interpolated)	2.40×10^{-5}	

(Note - these numbers include radioactive decay)

Point Estimates of Intake

- Intake = $V/m(t)$ where:
 - V = value of bioassay result (Bq, Bq d⁻¹)
 - $m(t)$ = IRF for bioassay measurement at time t after intake
- Treat each data point as a separate trial
- Average separate estimates if consistent
- If not consistent, look at biokinetic model

Point estimates of intake

Day 70: $60 \text{ Bq} / 2.97 \times 10^{-5} = 2.02 \text{ MBq}$

Day 100: $50 \text{ Bq} / 2.60 \times 10^{-5} = 1.92 \text{ MBq}$

Day 130: $45 \text{ Bq} / 2.40 \times 10^{-5} = 1.88 \text{ MBq}$

Day 70: $0.25 \text{ MBq} / 0.136 = 1.84 \text{ MBq}$

The average is 1.92 MBq. The most reliable estimate might be 1.84 MBq, if lung counter was well calibrated. The “best” answer is 2 MBq, given the accuracy of the models.

Least Squares Fits

- **Unweighted LSF:**

$$\text{Intake} = \{\sum_i [V_i m(t_i)]\} / \{\sum_i [m(t_i)]^2\}$$

- **Weighted LSF:**

$$\text{Intake} = \{\sum_i V_i\} / \{\sum_i m(t_i)\}$$

LSF calculations

<u>Days post intake</u>	<u>V*m(t)</u>	<u>m(t)²</u>	<u>V</u>	<u>m(t)</u>
70	0.00178	8.82×10^{-10}	60	2.97×10^{-5}
100	0.00130	6.76×10^{-10}	50	2.60×10^{-5}
130	0.00108	5.76×10^{-10}	45	2.40×10^{-5}
Sums:	0.00416	2.13×10^{-9}	155	7.97×10^{-5}

Best estimate of initial intake:

unweighted: $0.00416 / 2.13 \times 10^{-9} = 1.95 \times 10^6 \text{ Bq}$

weighted: $155 / 7.97 \times 10^{-5} = 1.95 \times 10^6 \text{ Bq}$

Committed dose ($2 \times 10^6 \text{ Bq}$) \cdot ($3.4 \times 10^{-7} \text{ Sv/Bq}$) = 0.68 Sv

Things to remember

- **Not a good idea to combine WBC and excreta data if values differ by several orders of magnitude**
- **If the intake estimates via ULSF and WLSF differ quite a bit, the biokinetic model is probably wrong**
- **Can use $m(t)$ values to distinguish between Class D, W, and Y (or Type F, M, and S) intakes if sequential bioassay data are available**

Interpretation - Chronic Uptakes

$$A = I (\lambda_e)^{-1} (1 - e^{-\lambda_e t})$$

where: A = activity in the body (Bq)

I = rate of intake of activity (Bq/day)

λ_e = effective removal constant (day^{-1})

t = time since activity intake began (days)

$$\text{Daily excretion} = I \lambda_b (\lambda_e)^{-1}$$

where: λ_b = the biological removal constant

Quality Assurance

for dose calculations

- Primary determinant of dose quality is bioassay data quality
- Computer-based calculations must be periodically verified
- Results must be reviewed by an experienced dosimetrist
- Errors (where quantifiable) should be propagated through to final result

Remember Uncertainties

- Analytical results
- Daily variation in excretion
- Background variability
- Biokinetic model
- Particle size and solubility class
- Breathing rate
- Gastrointestinal uptake
- Etc., etc., etc.

Quality Control

- Maintain configuration control of software
- Double (if not triple) check data entry
- Remember to protect subject's privacy
- Consistency is a good quality indicator (all monitoring and scenario-type data)
- Exercise the system occasionally
- Somebody must understand all aspects of the internal dosimetry operation

More Things to Remember

- Two significant figures is pushing it
- Nobody behaves exactly like the models
- Keep records of everything
- Ensure management is aware of accuracy of bioassay data and resulting doses
- Try not to allow yourself to be forced to draw a conclusion you're really not comfortable with

References

NCRP 87 - Use of Bioassay Procedures for
Assessment of Internal Radionuclide Deposition

NRC Reg. Guide 8.11 - Applications of Bioassay for
Uranium

NRC Reg. Guide 8.20 - Applications of Bioassay for
125 and I-131 I-

ANSI N13.14 - Internal Dosimetry Programs for
Tritium Exposure - Minimum Requirement

AECL - 6478 - Annual Limits on Intake, Organ
Burdens, and Excretion Rates for Occupational
Exposure to Uranium

References

NUREG/CR-4884 - Interpretation of Bioassay
Measurements

ICRP 54 - Individual Monitoring for Intakes of
Radionuclides by Workers: Design and Interpretation

NRC Reg. Guide 8.9 - Acceptable Concepts, Models,
Equations, and Assumptions for a Bioassay
Program

HPS N13.30 - Performance Criteria for Radiobioassay

Internal Radiation Dosimetry--Proc. HPS 1994 Summer School (O.
G. Raabe, ed., Medical Physics Publishing)